Core Viewpoint - A class action securities lawsuit has been filed against Caribou Biosciences, Inc. alleging securities fraud that affected investors between July 14, 2023, and July 16, 2024 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Caribou Biosciences overstated the safety, efficacy, and durability of its product CB-010 compared to approved CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [2]. - It is alleged that Caribou was at significant risk of having insufficient cash and liquidity to fund its business operations, including preclinical research for its allogeneic CAR-NK platform [2]. - The lawsuit suggests that these issues were likely to have a significant negative impact on Caribou's business and operations, rendering the defendants' public statements materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 24, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Caribou Biosciences, Inc. regarding a class action lawsuit due to alleged misleading statements and financial risks associated with the company's product CB-010 [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from July 14, 2023, to July 16, 2024 [2]. - Allegations include that Caribou overstated the safety, efficacy, and durability of CB-010 compared to approved therapies, and failed to disclose significant risks regarding cash and liquidity [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 24, 2025, to potentially become lead plaintiffs [3]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated the company's stock [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Caribou Biosciences, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's product safety and financial stability [2][4]. Group 1: Allegations Against Caribou - The complaint alleges that Caribou overstated the safety, efficacy, and durability of its product CB-010 compared to approved therapies [4]. - It is claimed that Caribou was at significant risk of insufficient cash and liquidity to fund its operations, including preclinical research [4]. - The allegations suggest that these issues could have a significant negative impact on Caribou's business and operations [4]. Group 2: Stock Performance and Analyst Reactions - Following the announcement of updated clinical data on June 2, 2024, Caribou's stock was downgraded by Evercore ISI, with a price target reduction from $13.00 to $3.00 [5]. - On June 3, 2024, Caribou's stock price fell by $0.735, or 25.52%, closing at $2.145 per share [6]. - After disclosing workforce reductions and the discontinuation of preclinical research on July 16, 2024, the stock price fell by $0.09, or 3.3%, to close at $2.64 per share on July 17, 2024 [7]. Group 3: Legal Proceedings and Class Action - Investors who suffered losses exceeding $75,000 between July 14, 2023, and July 16, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - There is a deadline of February 24, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Caribou [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [8].

Core Viewpoint - A class action securities lawsuit has been filed against Caribou Biosciences, Inc. alleging securities fraud that affected investors between July 14, 2023, and July 16, 2024 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Caribou Biosciences overstated the safety, efficacy, and durability of its product CB-010 compared to approved CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [2]. - It is alleged that Caribou faced significant risks regarding insufficient cash and liquidity to fund its business operations, including preclinical research for its allogeneic CAR-NK platform [2]. - The lawsuit suggests that these issues were likely to have a substantial negative impact on Caribou's business and operations, rendering the defendants' public statements materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 24, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Caribou Biosciences, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its business operations and the viability of its product CB-010 during the specified class period [1][3]. Group 1: Class Action Details - The class action represents investors who purchased securities between July 14, 2023, and July 16, 2024, with a deadline of February 24, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Allegations Against Caribou - The complaint claims that Caribou exaggerated the safety, effectiveness, and long-term viability of CB-010 compared to existing CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [3]. - It is alleged that Caribou faced significant risks regarding cash, liquidity, and capital necessary for ongoing business operations, including preclinical research related to its allogeneic CAR-NK platform [3]. - The issues raised in the complaint are expected to severely impact Caribou's business and operations, rendering the defendants' public statements materially false and misleading throughout the class period [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Caribou Biosciences, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Caribou securities is from July 14, 2023, to July 16, 2024, and the lead plaintiff deadline is February 24, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]. Group 3: Case Allegations - The lawsuit alleges that Caribou made false and misleading statements regarding the safety, efficacy, and commercial prospects of its product CB-010, particularly in comparison to approved therapies [4]. - It is claimed that Caribou was at significant risk of insufficient cash and liquidity to fund its operations, which could negatively impact its business [4]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, leading to investor damages when the truth was revealed [4].

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=128936&from=4CLASS PERIOD: Jul ...

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the “Class Period”), of the important February 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...